Open an account

MDxHealth SA

MDXH · NASDAQ

$0.1833−$0.0007 (−0.38%)TodayMarket closed ·
Prev close $0.184

About MDXH

MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

Employees
312
Headquarters
Herstal, Liege
Listed
Jun 26, 2006
Sector
Health Care
Industry
Biotechnology
Website
mdxhealth.com

MDXH key statistics

Market cap
17.49M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.68M
Volume
656.46K
Open price
$0.192
High today
$0.192
Low today
$0.1775
52 Week high
$5.33
52 Week low
$0.171

MDxHealth SA (MDXH) at a glance

MDxHealth SA (MDXH) last traded at $0.1833, with a market cap of 17.49M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.1775 and $0.192. The current price is 3.3% above the day's low and 4.5% below its high.

Volume so far is 656.46K shares, below the average of 1.68M shares a day.

Over the past year MDxHealth SA has ranged from $0.171 to $5.33, and now sits 0% of the way up that range.

MDxHealth SA met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.18 per share against an estimate of -$0.1979.

The average analyst price target is $1.15, 526.0% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 6 analystsAvg $1.15
Low
$0.505
Now
$0.1833
High
$2.10

MDXH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 18.8% on average.

  1. Q3 FY24: reported -$0.40 per share against an estimate of -$0.2754
  2. Q4 FY24: reported -$0.14 per share against an estimate of -$0.1958
  3. Q1 FY25: reported -$0.19 per share against an estimate of -$0.1326
  4. Q2 FY25: reported -$0.15 per share against an estimate of -$0.1265
  5. Q3 FY25: reported -$0.16 per share against an estimate of -$0.1102
  6. Q4 FY25: reported -$0.17 per share against an estimate of -$0.1285
  7. Q1 FY26: reported -$0.17 per share against an estimate of -$0.155
  8. Q2 FY26: reported -$0.18 per share against an estimate of -$0.1979

MDXH news

  • Avi Kapoor

    Crude Oil Jumps 3%; Citizens Financial Earnings Top Views

  • Avi Kapoor

    Dow Surges 250 Points; M&T Bank Posts Upbeat Q3 Earnings

  • Vandana Singh

    MDxHealth Says Well-Positioned to 'Return to Positive EBITDA'

  • Press releaseGlobe Newswire

    These Biotech Breakouts and Squeeze Setups Could Be Just Getting Started

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Avi Kapoor

    Dow Falls Over 100 Points; US Consumer Sentiment Declines In August

  • Avi Kapoor

    US Stocks Mixed; Retail Sales Fall In July

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.